Actuate Therapeutics, Inc. Common Stock

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Actuate Therapeutics to Present at The Citizens Life Sciences Conference

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers